FDA Accepts IND Application for Neoantigen-Directed T-Cell Therapy

Article

The CAR T-cell product has a neoantigen-specific T-cell receptor that is located and classified via a T-cell receptor discovery platform.

FDA Accepts IND Application for Neoantigen-Directed T-Cell Therapy | Image Credit: © VanHope - stock.adobe.com.

The T-cell receptor discover platform assesses well-characterized, naturally optimized, cytotoxic T-cell receptors while maintaining flexibility for multi-targeting via robust T-cell receptor combinations.

The FDA has accepted an investigational new drug (IND) application for a neoantigen T-cell receptor–based T-cell therapy, according to a press release from developer, Adaptive Biotechnologies.1

The T-cell receptor–based product is the first to advance into development in oncology based on collaboration between Adaptive Biotechnologies and Genentech. The treatment relies on a T-cell receptor discovery platform to identify and characterize a neoantigen-specific T-cell receptor. According to the company, novel T-cell therapies are in development for several cancer types with the goal of creating a new treatment paradigm allowing for therapies to be tailored based on individual patients’ needs.

“This IND acceptance reaffirms the value of our immune medicine platform and Adaptive’s ability to identify and characterize clinical grade, therapeutic T-cell receptors, which is the cornerstone of our drug discovery capabilities,” Chad Robins, chief executive officer and co-founder at Adaptive Biotechnologies, said in the press release.

Specifically, the T-cell receptor discovery platform is capable of identifying naturally-occurring and robust T-cell receptors that may be used for clinical development.2 It is reported that over 8000 unique, antigen-specific T-cell receptors have been observed with 600 clinically important targets.

Through the use of blood samples, antigens and proteomes can be targets, with class I and II human leukocyte antigens being of particular interest. Investigators indicate that T-cell receptors are naturally occurring and fully human, and have undergone thymic selection.

The model is said to have a high throughput and high sensitivity, as well as being capable of testing for thousands of antigens within one screening. It can also pinpoint ultra-low frequency T-cell receptors and pair hundreds of thousands of alpha/beta chains. Clinical candidates are selected by querying the whole T-cell receptor repertoire. The platform assesses well-characterized, naturally optimized, cytotoxic T-cell receptors while maintaining flexibility for multi-targeting via robust T-cell receptor combinations.

Following a blood draw, the best neoantigen-specific T-cell receptors can be identified in real time, which are capable of targeting unique mutations. It is believed that patient-specific T-cell receptors may be used to create personalized cellular agents. This could be a shared product containing a T-cell receptor capable of targeting a shared cancer neoantigen or a private T-cell therapy product that has multiple T-cell receptors that home in on an individual’s specific tumor neoantigens.

References

  1. Adaptive Biotechnologies announces FDA acceptance of Genentech’s investigational new drug application for the first neoantigen-directed T-cell therapy product in oncology. News release. Adaptive Biotechnologies. May 9, 2023. Accessed May 9, 2023. https://bit.ly/42lV64v
  2. Drug discovery: TCR therapeutics. Adaptive Biotechnologies. Accessed May 9, 2023. https://bit.ly/3VKE2m9
Recent Videos
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Related Content